Cefdinir for Pneumonia
Cefdinir is NOT a recommended first-line agent for community-acquired pneumonia (CAP) in adults according to current guidelines, though it may serve as an alternative oral cephalosporin option in children with specific indications.
Adults
The 2019 IDSA/ATS guidelines for CAP do not include cefdinir among recommended regimens for outpatient adults 1. The preferred agents are:
For healthy adults without comorbidities:
- Amoxicillin 1 g three times daily (first choice)
- Doxycycline 100 mg twice daily
- Macrolide (only if local pneumococcal resistance <25%)
For adults with comorbidities (heart, lung, liver, renal disease; diabetes; alcoholism; malignancy; asplenia):
- Combination therapy: Amoxicillin/clavulanate OR cephalosporin (cefpodoxime 200 mg twice daily or cefuroxime 500 mg twice daily) PLUS macrolide or doxycycline
- Monotherapy: Respiratory fluoroquinolone (levofloxacin 750 mg daily, moxifloxacin 400 mg daily)
Key limitation: Cefdinir lacks adequate coverage for atypical pathogens (Mycoplasma, Chlamydophila, Legionella) that commonly cause CAP, which is why combination therapy or fluoroquinolones are preferred when broader coverage is needed.
Pediatric Patients (≥6 months to 12 years)
Cefdinir serves as an alternative oral agent in specific pediatric scenarios 2:
Dosing for Children
According to FDA labeling and pediatric guidelines 3:
- Standard dose: 14 mg/kg/day (maximum 600 mg/day)
- Can be given as: 7 mg/kg every 12 hours OR 14 mg/kg once daily
- Duration: Typically 10 days for pneumonia
Specific Indications in Children
For β-lactamase producing Haemophilus influenzae pneumonia:
- Cefdinir is listed as an alternative oral agent (along with cefixime, cefpodoxime, or ceftibuten) 2
- Preferred oral therapy remains amoxicillin/clavulanate
For penicillin-susceptible Streptococcus pneumoniae:
- Cefdinir is listed as an alternative to amoxicillin (the preferred agent) 2
- Other alternatives include cefpodoxime, cefuroxime, and cefprozil
NOT appropriate for:
- Atypical pneumonia (Mycoplasma, Chlamydophila) - requires macrolides
- Staphylococcus aureus pneumonia
- Severe pneumonia requiring hospitalization
Practical Dosing Chart (from FDA label) 3
| Weight | 125 mg/5 mL suspension | 250 mg/5 mL suspension |
|---|---|---|
| 9 kg (20 lbs) | 2.5 mL q12h or 5 mL q24h | Use 125 mg/5 mL product |
| 18 kg (40 lbs) | 5 mL q12h or 10 mL q24h | 2.5 mL q12h or 5 mL q24h |
| 27 kg (60 lbs) | 7.5 mL q12h or 15 mL q24h | 3.75 mL q12h or 7.5 mL q24h |
| 36 kg (80 lbs) | 10 mL q12h or 20 mL q24h | 5 mL q12h or 10 mL q24h |
| ≥43 kg (95 lbs) | 12 mL q12h or 24 mL q24h | 6 mL q12h or 12 mL q24h |
Clinical Evidence
While cefdinir demonstrated equivalence to cefaclor in one adult CAP trial (80% vs 79% cure rates) 3, 4, it showed non-equivalence to amoxicillin/clavulanate in a European study (80% vs 89% cure rates) 3. This inferior performance, combined with lack of atypical coverage, explains its absence from current adult guidelines.
Special Populations
Renal insufficiency (CrCl <30 mL/min):
- Adults: 300 mg once daily
- Children: 7 mg/kg once daily (maximum 300 mg)
Hemodialysis patients:
- 300 mg (or 7 mg/kg) every other day
- Give 300 mg after each dialysis session
Important Caveats
- Food reduces absorption by 16-44% with capsules and suspension respectively, though this is not considered clinically significant 3
- Diarrhea is more common with cefdinir (13.7%) compared to other cephalosporins (5.3%) 4
- Suspension must be discarded after 10 days at room temperature 3
- No activity against MRSA or atypical pathogens
Bottom line: Use amoxicillin or amoxicillin/clavulanate as first-line in children; reserve cefdinir for β-lactamase producing H. influenzae when amoxicillin/clavulanate is not tolerated. In adults, choose guideline-recommended regimens that provide atypical coverage.